Podcasts about IV

Pullups a Seat, This is a Problem.Previous Interview with Sarah: https://www.youtube.com/watch?v=8Zs0Jf5CoC4Shop EveryLife: https://everylife.com/Enjoy :)Enjoy :)====================================Matt's Town Square Application: https://soj.ooo/Join this channel to get access to perks:https://www.youtube.com/channel/UC4rC0QxBD1eRPKMHIIpL0vA/joinhttps://merchlabs.com/collections/matt-kimGet Your Free Thinker Apparel Today!Donate!https://www.mattkimpodcast.com/support/FREE THINKER ARMY DISCORD:https://discord.gg/2juHnR6DPzTELEGRAM EDIT ZONE:https://t.me/+IV-skn-OXyw1MTcxFollow Matt!Instagram: https://www.instagram.com/mattattack009/Twitter:  https://twitter.com/FreeMattKimRumble:  https://rumble.com/c/FreeMattKimTikTok:  https://www.tiktok.com/@freemattkimBusiness Inquiries Please Email mattkimpodcast@protonmail.com====================================Time Stamps:0:00 Make More Babies5:39 The Process of Growing A Business (Lessons)7:27 Going International (EveryLife Korea)13:25 Becoming Pro-Family (Anti-Selfish)17:51 Korea is a Warning!22:12 Work/Mom Balance (Advice)26:28 Family Mission (Decision Making)

In this episode of the podcast Mining Minds sits down with two remarkable women reshaping the health and wellness landscape: Melissa Montalvo and Josie Cervantes of Elko Replenish Med Spa. Together, they reveal how their professional experiences—from ER trauma to urgent care frustrations—sparked a vision: to create a space that not only heals but empowers. That vision became Elko Replenish Med Spa, a modern facility focused on hormone therapy, IV nutrition, weight management, and overall wellness. The duo discusses how their clinic is bridging the gap between conventional medicine and preventative care, especially for miners and working professionals in Northern Nevada. From hormone optimization and detox treatments to addressing male and female health in the mining industry, Melissa and Josie are revolutionizing rural medicine with empathy, education, and science-backed solutions. Join Mining Minds as we welcome Elko Replenish Med Spa to the Face!  Episode Sponsors: GBC-NORCAT Heavy Metal Equipment & Rentals Motor Mission Machine and Radiator Episode Chapters: 2:23 South Texas Roots 9:27 Basson to Basketball 37:26 Medical Training Meets Bureaucracy 43:07 Leap of Faith 52:48 The Birth of Elko Replenish Med Spa 1:21:09 Hormones, Bro Science, and Real Health 1:41:31 The Vision

Legendary producer Gale Anne Hurd answers our questions at The Forbidden Worlds Film Festival! Video version here: https://youtu.be/IqpzoUBZXsE In more detail, a group of press each ask Gale Anne Hurd questions during FWFF and this is the first half of the roundtable! Questions are varied and come from several creators, talking about Gale's mentors & inspirations, her early and later film & TV production work, why she loves film, her apathy of sequels she didn't produce and others, all bringing exclusive insight into her iconic career with projects like as Aliens, Terminator, The Abyss, The Walking Dead and more! Find part 2 of this roundtable interview on Spider-Dan's podcast feed: www.youtube.com/@dan_bores Make sure you check out Dan & Mike's other coverage at FWFF including more interviews and their reviews of Battle Beyond The Stars, Orca, She Creature & The Whale God on this feed, and check out Spider-Dan's feed for the other half of their reviews, including Waterworld, The City Of Lost Children, Tremors, Alligator and more: https://www.youtube.com/watch?v=zBGeVcphpNw&list=PLcO1Ib_BGD8Ztm2q8Rs_s6C9MP4nNaV9m&index=1 For more information, visit www.forbiddenworldsfilmfestival.co.uk Make sure you follow & subscribe to Spider-Dan's podcast as much of the coverage is split between the feeds/YouTube channels! https://spiderdanandthesecretbores.com & www.patreon.com/spiderdanandthesecretbores Others at the GAH roundtable include Rob Hill: https://youtube.com/@TheBadMovieBible, Matthew Buck: https://youtube.com/@FilmBrain, Fergus: https://instagram.com/fergmaster, Nathan Hardie: https://linktr.ee/hardiewrites, Jon Melville: linktr.ee/jonathanmelville Check out the special preview episodes Mike & Dan did, where Mike reviewed the 1985 movie Young Sherlock Holmes for the 40th Anniversary of the movie, where a special showing (& cast Q&A) is happening! For Dan's preview episode, he delved into the Waterworld sequel comic; Children Of Leviathan! Star Wars fans must check Mike's in-depth reviews, breakdowns & things you missed episodes of Season 2 of Andor, on any podcast app or on YouTube: https://podfollow.com/starwarschitchat & https://youtube.com/@starwarschitchat All Patreons have been receiving bonus episodes, including reviews on Thunderbolts, Superman III & IV, Venom 3 and more, as well as early access! Support at www.patreon.com/GenuineChitChat or https://ko-fi.com/GenuineChitChat Guest Spots: Another episode of Disney Discussions is out where Mike & Dan spoke about Lilo & Stitch 1 & 2 with Megan, Ria & guest Natalie! https://tinyurl.com/2bs7kker Mike recently reviewed Superman '78, Superman II and the Super/Man documentary on the 20th Century Geek podcast, while Dan spoke about Superman IV! https://pod.fo/e/2bea07 Mike was on Reckless Rebellion to talk about Andor's Prison Arc from S1, listen here: https://pod.fo/e/2c28cc Find all of Mike's social media & other links at https://linktr.ee/GenuineChitChat Please review/rate, subscribe and share – it helps the show out an incredible amount!

What if the secret to unlocking better sleep, glowing skin, and emotional clarity was as simple as swapping your morning brew?In this deeply personal solocast, I share the raw truth behind what happened when I gave up coffee for 30 days. No preachy detoxes, no trendy biohacking—just the real-life physical, emotional, and energetic shifts I experienced by making one small, intentional change. From the withdrawal symptoms (hello, rage naps!) to rediscovering ancestral rituals through chai, this is a story of presence over pressure, and nourishment over numbing.If you're burnt out, wired, and always reaching for your next fix, this episode is your invitation to reset.What you'll get out of this episode… The emotional, physical, and hormonal signs that it might be time to rethink your caffeine habitsWhat really happens to your energy, sleep, and mood when you quit coffee cold turkeyWhy chai is more than a drink—it's an ancestral nervous system ritualThe Ayurvedic ingredients (like saffron, cinnamon & cardamom) that support glow, gut health & calmThe truth about coffee addiction that no one talks about: identity, not just chemistryHow I replaced the “push productivity” mindset with presence and still got more doneA free downloadable chai ritual calendar to help you create your own slow mornings (get yours at ⁠⁠neetabhushan.com/chaitonics⁠⁠!)This episode is powered by Health NagMeet your new daily glow-up: Health Nag's Bioactive Collagen Jelly—the world's first collagen with Types I, II, III & IV for full-body support (skin, gut, joints & more).Tastes amazing. Absorbs fast. One spoon a day = science-backed resilience from the inside out.

Ocho años en prisión, un espejo roto de un centímetro y una decisión que cambió todo. Iván nos lleva al momento exacto donde tocó fondo en una celda de castigo con 40 personas, ratas y chinches, para contarnos cómo se convirtió en mentor de jóvenes y ejemplo vivo de que la reinserción social es posible. Desde ese momento crucial frente a un espejo roto en una celda de castigo con 40 personas, hasta convertirse en mentor de jóvenes en situación vulnerable, Iván nos comparte su transformación radical.Descubre cómo la Fundación Reinserta cambió su perspectiva, su historia de amor con Laura (una funcionaria que renunció por él), los desafíos de la paternidad a distancia, y su actual trabajo en justicia restaurativa.Iván nos habla sin filtros sobre la adicción, el sistema penitenciario mexicano, las dinámicas carcelarias, y cómo encontró propósito ayudando a niños sobrevivientes de violencia.Una conversación que desafía nuestros prejuicios sobre la justicia, el castigo y la posibilidad real de cambio. Un testimonio que nos invita a replantear qué significa verdaderamente la rehabilitación y la reparación del daño social.Para ver episodios exclusivos, entra aquí: https://www.patreon.com/Penitencia_mx¿Quieres ver los episodios antes que nadie? Obtén acceso 24 horas antes aquí: https://www.youtube.com/channel/UC6rh4_O86hGLVPdUhwroxtw/joinVisita penitencia.comSíguenos en:https://instagram.com/penitencia_mx  https://tiktok.com/@penitencia_mx  https://facebook.com/penitencia.mx  https://x.com/penitencia_mx  Spotify: https://spotify.link/jFvOuTtseDbApple: https://podcasts.apple.com/mx/podcast/penitencia/id1707298050Amazon: https://music.amazon.com.mx/podcasts/860c4127-6a3b-4e8f-a5fd-b61258de9643/penitenciaRedes Saskia:https://www.youtube.com/@saskiandr - suscríbete a su canalhttps://instagram.com/saskianino  https://tiktok.com/@saskianino  https://x.com/saskianino

Paola Holguín denunció ante la Corte Suprema a la senadora Isabel Zuleta luego de pedir la salida de reclusosFiscalía ocultó pruebas sobre las conversaciones entre Juan Guillermo Monsalve e Iván Cepedapresidente Gustavo Petro suspendió la extradición de Willinton Henao Gutiérrez, alias “Mocho Olmedo”, cabecilla del “Frente 33″.Audios de Álvaro Leyva en poder de la Fiscalía Petro no pidió permiso para dirigirse a la ciudad de Manta en el Ecuador ¿Petro se reunió con alias Fito? Art 196 de la CP ordena dar a conocer su rutaMontealegre anuncia su misión por la paz total de PetroLa Fiscalía abrió indagación por los audios filtrados en los que se escucha al excanciller Álvaro Leyva hablar de un supuesto golpe de estado contra el presidente Gustavo PetroDay Vasquez dice que no tiene protección del Estado para contar todo lo que sabe.Qué pasa con los pasaportes

Dylan Beynon: At-Home Ketamine Therapy, Big Pharma Pushback, and the Future of Psychedelic Accessibility In this episode, Joe Moore welcomes Dylan Beynon, CEO and Founder of Mindbloom, one of the largest providers of legal, at-home ketamine therapy in the U.S. Dylan shares the deeply personal story that led him to psychedelic medicine—including the tragic loss of his mother and sister to addiction and mental illness—and how these experiences continue to fuel his mission to make psychedelic therapy affordable and accessible for all. Mindbloom has now facilitated over 654,000 sessions across 38 states, offering both sublingual and subcutaneous (injectable) ketamine in a comprehensive treatment program that includes preparation, integration, music, journaling, and even generative AI art. The conversation dives into common criticisms of at-home ketamine, the benefits of guided treatment over IV infusions, and the disturbing influence of Big Pharma in media narratives—especially the growing PR push behind SPRAVATO. Dylan also breaks down what makes Mindbloom's outcomes stand out, why they recently added injectable ketamine, and how their safety data challenges popular misconceptions. Joe and Dylan also touch on the potential future of at-home MDMA therapy, regulatory hurdles, and what it will take to scale these powerful treatments to millions of people in need. If you're in the psychedelic field, considering ketamine therapy, or curious about the ethics and economics of psychedelic medicine, this episode offers a powerful look behind the curtain. Resources: Mindbloom.com Vital Psychedelic Training

Granulomatosis with Polyangiitis (GPA) – Recognition and Management in the ED Hosts: Phoebe Draper, MD Brian Gilberti, MD https://media.blubrry.com/coreem/content.blubrry.com/coreem/GPA.mp3 Download Leave a Comment Tags: Rheumatology Show Notes Background A vasculitis affecting small blood vessels causing inflammation and necrosis Affects upper respiratory tract (sinusitis, otitis media, saddle nose deformity), lungs (nodules, alveolar hemorrhage), and kidneys (rapidly progressive glomerulonephritis) Can lead to multi-organ failure, pulmonary hemorrhage, renal failure Red Flag Symptoms: Chronic sinus symptoms Hemoptysis (especially bright red blood) New pulmonary complaints Renal dysfunction Constitutional symptoms (fatigue, weight loss, fever) Workup in the ED: CBC, CMP for anemia and AKI Urinalysis with microscopy (hematuria, RBC casts) Chest imaging (CXR or CT for nodules, cavitary lesions) ANCA testing (not immediately available but important diagnostically) Management: Stable patients: Outpatient workup, urgent rheumatology consult, prednisone 1 mg/kg/day Unstable patients: High-dose IV steroids (methylprednisolone 1 g daily x3 days), consider plasma exchange, cyclophosphamide or rituximab initiation, ICU admission Conditions that Mimic GPA: Goodpasture syndrome (anti-GBM antibodies) TB, fungal infections Lung malignancy Other vasculitides (EGPA, MPA, lupus)

Link de boletos tour 2025https://linktr.ee/semesubioelmuertoGrupo de Facebook nuevo https://www.facebook.com/groups/97229...Link para el show de Ivánhttps://linktr.ee/soyivanmendozaaLink para el show de Alex Quirozhttps://linktr.ee/soyalexquirozzINSTAGRAM  / soyivanmendoza    / soyalexquiroz    / solinstandup  SMSEM CREW:   / flaquimedios  La flaquita:   / putzulbrizuela  Flaquito:   / albertoo_brizuela  FlaquiMich:   / mich_xh  Silvia:   / _silviasiu  Joch:   / elmismojoch  Soke:   / sokedistreeto  Audio Barry:   / pirrus_  

Cuéntanos tu experiencia como conductor de plataforma o usuario en “Historias De Un Taxi”… Nesty y Karly B lanzan el remix del éxito “Ella Puede” … El resumen deportivo con Iván "El Pollo"…. Horóscopitos …. Mariana Ochoa presenta “Ya Lo Sabía” en colaboración con Jonathan Becerra … Pero primero arrancamos con nuestro clásico “Chismecito Tlacuachero”.

In this episode, we talk about: a guy who didn't know what potatoes were, an AI chatbot getting worried about their partner, some pizza that should've stayed in the garbage, a listener who came across a man whose moniker is now Mr. Poopy Buttcheeks, and a guy who is excited to see his wife in the delivery room. We also have a circle jurdge of which crime solving group we'd join as a polycule. ⁠⁠⁠⁠⁠⁠⁠Judgies Merch is Available HERE!⁠⁠⁠⁠⁠⁠⁠ Want fun, cool stickers and MORE? ⁠⁠⁠⁠⁠⁠⁠www.aurorascreaturecorner.store⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠Palestine Children's Relief Fund⁠⁠⁠⁠⁠⁠⁠ Donation Link Edited by: ⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@currentlyblinking⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠https://twitter.com/currentlyblink⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠https://tiktok.com/@currently.blinking⁠⁠⁠⁠⁠⁠⁠ Our Patreon is officially open, if you want to see extra content go check it out!  ⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/JudgiesPod ⁠⁠⁠⁠⁠⁠⁠ Send us mail! (Addressed However You'd Like)  P.O. Box 58 Ottawa, IL 61350  Leave a Review!  ⁠⁠⁠⁠⁠⁠⁠https://podcasts.apple.com/us/podcast/the-judgies/id1519741238⁠⁠⁠⁠⁠⁠⁠  Follow us on Twitter: ⁠⁠⁠⁠⁠⁠⁠https://twitter.com/judgiespod⁠⁠⁠⁠⁠⁠⁠ Follow us on Instagram: ⁠⁠⁠⁠⁠⁠⁠https://instagram.com/judgiespod⁠⁠⁠⁠⁠⁠⁠  Intro Music by: Iván  ⁠⁠⁠⁠⁠⁠⁠https://open.spotify.com/artist/5gB2VvyqfnOlNv37PHKRNJ?si=f6TIYrLITkG2NZXGLm_Y-Q&dl_branch=1⁠⁠⁠⁠⁠⁠⁠  Time Stamps: 0:00 Intro 5:58 What Are Potatoes? 13:21 "I Come Again" 19:24 Trash Pizza 26:07 Friend Can't Feed Baby 32:26 Break 32:34 CJ: Mystery Solving Polycule 47:17 LS Sound 49:16 LS Story 56:43 Delivery Room Second Thoughts 1:03:29 Outro Story Links: What Are Potatoes? "I come again" DELETED Trash Pizza DELETED Friend Can't Feed Baby DELETED Delivery Room Second Thoughts Learn more about your ad choices. Visit megaphone.fm/adchoices

During the last two days, we have practiced and proclaimed the gospel to our community. Both Love Day and Freedom Celebration were outward expressions of the good news about Jesus Christ loving the world. But why not make it a lifestyle that continues year-round? Today we will explore four reasons Paul the apostle was not ashamed of the gospel.I. Because It's Good NewsII. Because It's God's PowerIII. Because It's Given FreelyIV. Because It Gets Us RightTalk with God: Meditate on “the righteousness of God” (v. 17) and spend time in worship as you thank Him for the salvation and freedom He's given you through HisSon's sacrifice.Talk with others: Come alongside a believing friend or family member facing sorrow or difficulty this week and encourage them to rest in God's grace and continue to “live by faith” (v. 17).Talk with kids: Why is Jesus the perfect and final sacrifice for sin?

Faith Roswell at The Forbidden Worlds Film Festival talks about her favourite movies and book! In the first of Mike & Dan's FWFF interviews, they had the pleasure of speaking with Faith Roswell about her book; Movie Monsters Of The Deep, who her Film Festival legend would be, a deep see movie few people have seen, her love of Alex Garland, why she wrote her novel and more! Faith's social media @FaithRoswellOfficial and website: www.faithroswell.co.uk Make sure you check out their reviews of Battle Beyond The Stars, Orca, She Creature & The Whale God on this feed, and check out Spider-Dan's feed for the other half of their reviews, including Waterworld, The City Of Lost Children, Tremors, Alligator and more! For more information, visit www.forbiddenworldsfilmfestival.co.uk For visual elements, check out the video version on YouTube: https://youtube.com/GenuineChitChat Make sure you follow & subscribe to Spider-Dan's podcast as much of the coverage will be split between the feeds/YouTube channels! https://spiderdanandthesecretbores.com & www.patreon.com/spiderdanandthesecretbores Make sure you check out the special preview episodes Mike & Dan did, where Mike reviewed the 1985 movie Young Sherlock Holmes for the 40th Anniversary of the movie, where a special showing (& cast Q&A) is happening! For Dan's preview episode, he delved into the Waterworld sequel comic; Children Of Leviathan! Check out Mike's in-depth reviews, breakdowns & things you missed episodes of Season 2 of Andor, on any podcast app or on YouTube: https://podfollow.com/starwarschitchat & https://youtube.com/@starwarschitchat All Patreons have been receiving bonus episodes, including reviews on Thunderbolts, Superman III & IV, Venom 3 and more, as well as early access! Support at www.patreon.com/GenuineChitChat or https://ko-fi.com/GenuineChitChat Guest Spots: Another episode of Disney Discussions is out where Mike & Dan spoke about Lilo & Stitch 1 & 2 with Megan, Ria & guest Natalie! https://tinyurl.com/2bs7kker Mike recently reviewed Superman '78, Superman II and the Super/Man documentary on the 20th Century Geek podcast, while Dan spoke about Superman IV! https://pod.fo/e/2bea07 Mike was on Reckless Rebellion to talk about Andor's Prison Arc from S1, listen here: https://pod.fo/e/2c28cc Find all of Mike's social media & other links at https://linktr.ee/GenuineChitChat Please review/rate, subscribe and share – it helps the show out an incredible amount!

Call while He is near I. Seek the LORD II. Call upon Him III. Forsake wicked ways IV. Return to the LORD V. Trust His mercy

Neste episódio especial do podcast filosófico da Nova Acrópole, celebrando o Dia da Arte, o tema é o cinema e sua profunda conexão com a filosofia. Recebemos Gabriel Nocera, voluntário da Nova Acrópole em São Paulo e diretor de animação, que compartilha sua experiência na produção audiovisual e o valor filosófico presente em seu trabalho. A conversa conduzida por Pedro Guimarães e Marcelo Silveira, diretor do Instituto Tristan, aborda o processo criativo na animação, a importância da autenticidade nas narrativas, e como o cinema pode ser expressão de uma verdade interior e universal. Gabriel destaca sua trajetória com a série “Tamas e Rajas”, inspirada na filosofia indiana, e reflete sobre a busca pela unidade por meio da arte — tema central das comemorações deste ano. Através de exemplos concretos, como a importância de cada detalhe visual em uma cena, ele demonstra como o cinema pode unificar elementos diversos em uma obra coerente e significativa. A filosofia aparece, assim, como um alicerce para compreender a natureza humana e criar narrativas que inspirem valores e transformação. Participantes: Gabriel Nocera, Marcelo Silveira e Pedro Guimarães Trilha Sonora: Symphony No. 1 in D major, IV. Finale – Molto vivace, de Sergei Prokofiev

Con esta ola de calor, el mejor plan es refugiarse en el cine y os traemos muchas propuestas. El gran estreno comercial de la semana es 'Fórmula 1', la superproducción con Brad Pitt y Javier Bardem, también Santiago Segura busca hacer buenos números en taquilla con el público familiar en el cierre de su saga, y además en este episodio recordamos a dos grandes autores de nuestro cine, a José Luis Borau e Iván Zulueta. En 30 minutos os ponemos al día de todo el cine y las series. 

En entrevista con Ana Francisca Vega para MVS noticias, el periodista Iván Alamillo explicó que de acuerdo con documentos obtenidos por Mexicanos contra la Corrupción se dio a conocer que la UIF conocía desde 2024 de las transferencias por 47 mdd de los presuntos prestanombres de García Luna a Vector.See omnystudio.com/listener for privacy information.

El maestro Iván López Reynoso ha sido nombrado Director Principal de la Ópera de Atlanta de 2025 a 2028

El maestro Iván López Reynoso ha sido nombrado Director Principal de la Ópera de Atlanta de 2025 a 2028

Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency.  So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated.  Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations.  And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:    Dr. Diwakar Davar    @diwakardavar    Dr. Jason Luke @jasonlukemd Follow ASCO on social media:     @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn   Disclosures:     Dr. Diwakar Davar:      Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences     Consulting or Advisory Role: Instil Bio, Vedanta Biosciences     Consulting or Advisory Role (Immediate family member): Shionogi     Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences     Research Funding (Inst.): Zucero Therapeutics     Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy     Dr. Jason Luke:     Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX     Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine     Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure     Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)     Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

On today's episode of The Pod At The Palace, host Curtis Wilkerson salutes Adou Thiero for joining the Pro Hogs' fraternity and discusses his fit with the Lakers before diving into Arkansas GM Remy Cofield's press conference and what his involvement with John Calipari and the basketball program might look like. OFFICIAL MERCH: https://insidearkansas.myshopify.com/ #arkansas #razorbacks #football #basketball #baseball #sampittman #johncalipari SHOUTOUT TO OUR SPONSORS: BET SARACEN Arkansas' #1 Sports Betting App! Visit www.betsaracen.com to check out the latest spreads, lines, O/U, parlays, and more! BetSaracen has specials running every day that are unique to everyone here in the great, state of Arkansas! Download the BetSaracen app today on the Apple or Google Play store and get to winning big ONLY with BetSaracen…Arkansas' #1 Sports Betting App! https://apps.apple.com/us/app/saracen/id1612098207 ----------------------------------------------------------------------------- FREEDOM BOAT CLUB Summer is finally here, and where is a better place to spend your summer than on the lake? Don't own a boat? Cool. You don't need to. Freedom Boat Club of Arkansas has you covered! Freedom Boat Club gives you access to boats—without the commitment. This is boating that fits your lifestyle—fun, flexible, and stress-free. They take care of the boat—so you can simply enjoy the moment. Whether you prefer Greers Ferry Lake, Lake Hamilton, or a day on the River in Little Rock, Freedom Boat Club of Arkansas will help make your summer in the Natural State the best one yet! Check out their Instagram page www.instagram.com/freedomboatclubarkansas today to learn more about the benefits of joining the club! ----------------------------------------------------------------------------- BASIS HEALTH Basis Health is changing the way healthcare is delivered by providing mobile medical visits at the comfort of your home. A doctor will come to your home for urgent care, primary care, IV hydration and more! Basis Health… they are here for you when and where you need them most! Learn more at basishealth.org today! ----------------------------------------------------------------------------- HICKEY & HULL LAW Divorce & custody cases are too important to try and face alone. Let Hickey & Hull Law provide you with persistent & diligent representation to help guide you through the entire process. They have handled THOUSANDS of family law cases & have experienced nearly every scenario that may come up. Hickey & Hull Law have offices across the state of Arkansas in Fayetteville, Fort Smith, Little Rock, & Mena. You can call them today at 479-434-2414 or you can check out their website! Visit www.hickeyandhull.com! It's Hickey & Hull Law…Things Are About To Get Better! ----------------------------------------------------------------------------- HD ROOFING & CONSTRUCTION Storms can hit unexpectedly, so be sure to contact HD Roofing for your peace of mind with a free inspection. When you choose HD Roofing, you can rely on professionalism, top-quality materials and expert installation for all of your roofing needs! Learn more at HDArkansas.com! ----------------------------------------------------------------------------- LOOPER AUCTION & REALTY Why wait months—or even years—to sell your home the traditional way? At Looper Auction & Realty, we offer a faster, smarter option. Sell your home at auction. No repairs. No contingencies. No drawn-out negotiations. You set the terms, buyers compete, and you walk away with a firm closing date. Whether it's your home, an estate, or investment property, the auction method puts you in control—and gets it sold fast. Call Looper Auction & Realty at 479-996-4848 or visit LooperAuction.com. Looper Auction & Realty — Sold in 30, Closed in 30 Learn more about your ad choices. Visit megaphone.fm/adchoices

Semana de coches y carreras con un Brad Pitt macarra y con un Javier Bardem que es tan estrella que ya insulta en español. Los actores protagonizan 'Fórmula 1', una de las películas candidatas a taquillazo del verano. En este episodio la analizamos a fondo y charlamos con sus responsables. Además, Santiago Segura cierra la saga 'Padre no hay más que uno', tenemos varios estrenos interesantes del cine de autor como lo nuevo de Jia Zhangke y 'Ramón y Ramón', y recordamos el cine de José Luis Borau e Iván Zulueta. En televisión, charlamos con Santiago Korovsky, el actor y guionista argentino de 'División Palermo', con Óscar Casas de 'El gran salto' y os recomendamos varias series.

Sobre el joven socialista de 33 años aspirante a la alcaldía de New York, Zohan Mamdani, quien se impuso al exgobernador del estado Andrew Cuomo en la primera vuelta de estas elecciones y el alto flujo de turistas brasileños en el país durante la temporada de invierno, principalmente en centros de ski, Iván Valenzuela conversó con Paula Escobar y Marily Lüders, en una nueva edición de Rat Pack de Mesa Central.

La Fiscalía de Colombia pidió esta semana una condena por soborno y fraude procesal contra el expresidente Álvaro Uribe. Es el primer exmandatario colombiano en enfrentar un juicio penal en la historia del país. Entrevistamos al senador Iván Cepeda sobre este caso. Desde hace más de un año, el expresidente colombiano Álvaro Uribe es juzgado por supuestas presiones a testigos para que guardaran silencio sobre su presunta relación con los escuadrones antiguerrillas. Cadena de falsos testimonios Este histórico proceso comenzó en 2012, cuando Uribe denunció al senador Iván Cepeda por “buscar testimonios falsos” en cárceles para vincularlo con paramilitares. El senador, por su parte, acusa al expresidente de falsificar la verdad. “Uribe ha desplegado un inmenso esfuerzo por intentar eludir su responsabilidad penal, y el problema es que se ha desatado en cadena este intento de falsificar la verdad. Entonces se han ido acumulando los falsos testigos. Él tiene unos abogados oficiales, pero contrató unos abogados en la sombra. Personas que, francamente, han actuado de una manera delictiva. El abogado principal que utilizó Uribe para esa clase de manejos ilegales está hoy en juicio también, el señor Diego Cadena, que es un abogado que se hace llamar a sí mismo ‘abogánster'”, explica Cepeda. “Y hay otros intervinientes que han sido testigos o intermediarios de testigos que también están en juicio. Este juicio lo están afrontando también en otros escenarios, otras cinco personas. Y hay 19 de esos falsos testigos que la Corte Suprema de Justicia ha ordenado investigar. Entonces, el aparato que ha actuado está hoy seriamente interpelado por la justicia”, prosigue. “Está marcando un camino” La fiscal a cargo del caso, Marlene Orjuela, declaró en una audiencia que las pruebas sobre la responsabilidad del expresidente son “concluyentes”. El juicio avanza contra reloj, debido a que puede prescribir la segunda semana de octubre si no hay veredicto. Sin embargo, el senador Cepeda se muestra optimista y recalca la importancia de este juicio. “En Colombia ha existido una especie de manto de impunidad, de escudo de impunidad, para proteger a quienes han ejercido las máximas responsabilidades y quienes tienen el mayor poder en la sociedad colombiana. Así que esto está marcando un camino. Y es que no solamente guerrilleros, paramilitares, militares, sino también civiles que tradicionalmente han escapado a la justicia, sean llamados a rendir cuentas”, estima. “Ahora bien, esto también puede, si se interpreta correctamente, ser un camino hacia la reconciliación, hacia la paz, porque el poder satisfacer la justicia y los derechos de las víctimas es una base sólida para la paz y para la democracia”, concluye. Desde el inicio del juicio, Álvaro Uribe ha negado las acusaciones y asegura que se trata de un juicio con motivos políticos. Se espera que a finales de julio la jueza Sandra Heredia pueda emitir un fallo.

En Columnistas de Mesa Central, Iván Valenzuela conversó con Daniel Mansuy y Patricio Fernández sobre los escenarios para la izquierda después de la primaria oficialista y el panorama ante un eventual triunfo de Jeannette Jara.

#gardening  #podcast #gardentalk #vegetablegarden  #radio #influencer #gardentip #gardentalkradio #backyardgarden Email your questions to Gardentalkradio@gmail.com Or call 1-800-927-SHOW  Segment 4: Garden questions answered Sponsors of the show for 2025 Phyllom BioProducts of http://www.phyllombioproducts.comPomona pectin of https://pomonapectin.com/Dripworks of https://www.dripworks.com/Walton's Inc of https://www.waltonsinc.com/  Us code grow50 and save 10% off your order of $50 or more Natural green products of https://www.natgreenproducts.com/ use promo code freeship4meany size No More Bugs!Rescue of https://rescue.com/Jung Seeds of https://www.jungseed.com/category/talk-gardening use code 15GT25 to save 15% off ordersWind River Chimes of https://windriverchimes.com/Wisconsin Greenhouse Company of https://wisconsingreenhousecompany.com/Mantis of https://mantis.com/Summit Chemical of https://summitchemical.com/Iv organics of https://ivorganics.com/  Use radio10 to save 10% off your orderSoilmoist.com of https://www.soilmoist.com/products/soil-moist.phpDavid J Frank of https://davidjfrank.com/ Timber Pro Coatings of https://timberprocoatingsusa.com/products/internal-wood-stabilizer/Totally tomatos of totallytomato.com/category/talk-gardening use code 15GT25 to save 15% off ordersr.h.shumway https://www.rhshumway.com/category/talk-gardening  use code 15GT25 to save 15% off ordersVermont Bean https://www.vermontbean.com/category/talk-gardening use code 15GT25 to save 15% off ordersEdmunds Roses use code https://www.edmundsroses.com/category/talk-gardening 15GT25 to save 15% off ordersRoot and Rhizomes https://www.rootsrhizomes.com/category/talk-gardeninguse code 15GT25 to save 15% off ordersKarrikaid https://karrikaid.com/ Use Code Radio10 at checkout and get 10% your order  Tarps https://tarps.com/Sunwarrior https://sunwarrior.com/ Use code JOEYHOLLY25” that will get you 25% off all productsat checkout Grow Smart https://www.grosmart.com/  use code “radio” at check out and save 10% on your order Lawn symergy https://lawnsynergy.com/Durable green bed https://durablegreenbed.com/Tree IV https://treeiv.com/Brome Bird Care https://bromebirdcare.com/en/Chip Drop https://getchipdrop.com/For Jars of https://forjars.co/  Use the code: forjars25 to get a 10% discount on your orderAzure https://www.azurestandard.com/ Use Promo Code: JOEYANDHOLLY15 applied at checkout to get 15% off for new customers who open an account for the first time and place a minimum order of $100 or more, shipped to a drop location of their choice.Corba head hand tools https://www.cobrahead.com/ use code soil for 10% your order at checkout valid once per customer Soil Savvy https://www.mysoilsavvy.com/Phyllom Bioproducts http://www.phyllombioproducts.com/home.htmlShore and Chore https://shoreandchore.com/Dig Defence of https://digdefence.com/Weed Wrench  https://www.weed-wrench.com/home us code weed at check out to save $10.00 on your order Milk weed balm of https://milkweedbalm.com/ Use code: gardening for 20% off your orderOne sweet earth of https://onesweetearth.com/Amazon #Influencer page with products we use and trust from gardening to camping, household goods and even cat stuff. Over 500 items list  https://www.amazon.com/shop/thewisconsinvegetablegardener?ref=ac_inf_hm_vp

Welcome to our new show where we give legally not advice to our listeners! Call (850)JUDGIES to leave us a voicemail asking for some of our (again, not legally) advice! In this episode, we talk about: an uncle and an aunt hooking up in front of the family, some aux cord woes striking following a repeat playing of Combiation Taco Bell and Pizza Hut, an ex fiance who won't return belongings, a cat(?), a hook up who passed away, and one person asks how to get good at quick maffs. ⁠⁠⁠⁠⁠⁠⁠⁠Judgies Merch is Available HERE!⁠⁠⁠⁠⁠⁠⁠⁠ Want fun, cool stickers and MORE? ⁠⁠⁠⁠⁠⁠⁠⁠www.aurorascreaturecorner.store⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠Palestine Children's Relief Fund⁠⁠⁠⁠⁠⁠⁠⁠ Donation Link Edited by: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@currentlyblinking⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/currentlyblink⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠https://tiktok.com/@currently.blinking⁠⁠⁠⁠⁠⁠⁠⁠ Our Patreon is officially open, if you want to see extra content go check it out!  ⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/JudgiesPod ⁠⁠⁠⁠⁠⁠⁠⁠ Send us mail! (Addressed However You'd Like)  P.O. Box 58 Ottawa, IL 61350  Leave a Review!  ⁠⁠⁠⁠⁠⁠⁠⁠https://podcasts.apple.com/us/podcast/the-judgies/id1519741238⁠⁠⁠⁠⁠⁠⁠⁠  Follow us on Twitter: ⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/judgiespod⁠⁠⁠⁠⁠⁠⁠⁠ Follow us on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠https://instagram.com/judgiespod⁠⁠⁠⁠⁠⁠⁠⁠  Intro Music by: Iván  ⁠⁠⁠⁠⁠⁠⁠⁠https://open.spotify.com/artist/5gB2VvyqfnOlNv37PHKRNJ?si=f6TIYrLITkG2NZXGLm_Y-Q&dl_branch=1⁠⁠⁠⁠⁠⁠⁠⁠  Time Stamps: 0:00 Intro 1:46 Uncle and Aunt Hookup 16:01 Aux Cord Woes 24:16 Ex Fiance Blocked Me 31:22 Cat? 32:42 Hookup Passed Away 40:25 Quick Maffs 51:05 Outro Learn more about your ad choices. Visit megaphone.fm/adchoices

The 1995 tour was one of the most tumultuous for Pearl Jam in their history. Their Ticketmaster boycott was in full effect, so while shows were more affordable for their audience, tickets were tougher to acquire and venues were at a premium. Eddie at this time is dealing with struggles of being in the spotlight, and instead of opting to travel with the band, he spins records in a van driving from location to location on tour. There are historic shows that happen on this run like Red Rocks and Soldier Field, but everything comes to a head when they reach San Francisco. The night before the show, Ed comes down with a case of food poisoning and needs to take a trip to the ER. After getting IV fluids, he is still completely sick when it comes show time. However, he goes out there, makes it through seven songs and then walks off the stage no longer capable of playing. This episode looks back 30 years later after the infamous incident at Golden Gate Park. As luck would have it, Neil Young happened to be there that day originally slated to make a guest appearance prior to the Mirror Ball record's release three days later. While it was certainly a huge benefit to have him on hand in a desperate time of need, the crowd paid to see Eddie. They were restless throughout the entire set having to sit through unreleased songs off a brand new record in an unfathomable heat for San Francisco. For as incredible as the band's efforts were in this moment, winning over the crowd was a fruitless task. This is a jam packed episode with a lot to talk about. We'll cover the era and how the fallout from this show just narrowly avoided a break up, we'll talk about the crowd's reactions, Eddie's struggles and some of the oddities in song selection that included not one, but TWO versions of Rockin' In The Free World! We'll also invite our good friend, Mar Vigil, on to discuss what it was like to be there on that day. Visit the Concertpedia - http://liveon4legs.com Contact the Show - liveon4legspodcast@gmail.com Donate to the Show - http://patreon.com/liveon4legs

Iván Herrera hits the IL with a hammy strain, and Thomas Saggese gets the call-up. The Cards also snag Garrett Hampson off waivers while DFA'ing Jose Barrero. On the field, Burly is crushing June with a 161 wRC+ and just 8 Ks in 88 PAs—but Gormy's even hotter, slashing .289/.385/.607 with 5 bombs. Libby and Fedde are locked in, Maton's untouchable, and Andre Granillo grabs his first MLB win and save. We preview the road trip to Cleveland and Pittsburgh, shout out Cal Raleigh's historic homer binge, and check in on the latest from around the league. Have a question or comment for the show? Text or leave us a voicemail at: (848) 48-BIRDS (848-482-4737)Talking About Birds is listener supported on Patreon. Support the show and join our private discord server at: www.patreon.com/talkingaboutbirds.

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

On today's episode of The Pod At The Palace with Curtis Wilkerson: - Hindsight is 20/20, but should Adou Thiero have stayed at Arkansas? - Why Calipari's 1st Round NBA Draft pick streak getting snapped is ACTUALLY encouraging - 2026 mocks loaded with future Pro Hogs - Egor Ryzhov to... Florida State? SHOUTOUT TO OUR SPONSORS: BET SARACEN Arkansas' #1 Sports Betting App! Visit www.betsaracen.com to check out the latest spreads, lines, O/U, parlays, and more! BetSaracen has specials running every day that are unique to everyone here in the great, state of Arkansas! Download the BetSaracen app today on the Apple or Google Play store and get to winning big ONLY with BetSaracen…Arkansas' #1 Sports Betting App! https://apps.apple.com/us/app/saracen/id1612098207 ----------------------------------------------------------------------------- FREEDOM BOAT CLUB Summer is finally here, and where is a better place to spend your summer than on the lake? Don't own a boat? Cool. You don't need to. Freedom Boat Club of Arkansas has you covered! Freedom Boat Club gives you access to boats—without the commitment. This is boating that fits your lifestyle—fun, flexible, and stress-free. They take care of the boat—so you can simply enjoy the moment. Whether you prefer Greers Ferry Lake, Lake Hamilton, or a day on the River in Little Rock, Freedom Boat Club of Arkansas will help make your summer in the Natural State the best one yet! Check out their Instagram page www.instagram.com/freedomboatclubarkansas today to learn more about the benefits of joining the club! ----------------------------------------------------------------------------- BASIS HEALTH Basis Health is changing the way healthcare is delivered by providing mobile medical visits at the comfort of your home. A doctor will come to your home for urgent care, primary care, IV hydration and more! Basis Health… they are here for you when and where you need them most! Learn more at basishealth.org today! ----------------------------------------------------------------------------- HICKEY & HULL LAW Divorce & custody cases are too important to try and face alone. Let Hickey & Hull Law provide you with persistent & diligent representation to help guide you through the entire process. They have handled THOUSANDS of family law cases & have experienced nearly every scenario that may come up. Hickey & Hull Law have offices across the state of Arkansas in Fayetteville, Fort Smith, Little Rock, & Mena. You can call them today at 479-434-2414 or you can check out their website! Visit www.hickeyandhull.com! It's Hickey & Hull Law…Things Are About To Get Better! ----------------------------------------------------------------------------- HD ROOFING & CONSTRUCTION Storms can hit unexpectedly, so be sure to contact HD Roofing for your peace of mind with a free inspection. When you choose HD Roofing, you can rely on professionalism, top-quality materials and expert installation for all of your roofing needs! Learn more at HDArkansas.com! ----------------------------------------------------------------------------- LOOPER AUCTION & REALTY Why wait months—or even years—to sell your home the traditional way? At Looper Auction & Realty, we offer a faster, smarter option. Sell your home at auction. No repairs. No contingencies. No drawn-out negotiations. You set the terms, buyers compete, and you walk away with a firm closing date. Whether it's your home, an estate, or investment property, the auction method puts you in control—and gets it sold fast. Call Looper Auction & Realty at 479-996-4848 or visit LooperAuction.com. Looper Auction & Realty — Sold in 30, Closed in 30 Learn more about your ad choices. Visit megaphone.fm/adchoices

En Columnistas de Mesa Central, Iván Valenzuela conversó con Hernán Larraín y Cristián Valenzuela sobre el panorama para el oficialismo ante un posible triunfo de Jeannette Jara en las primarias del domingo 29 de junio.

#gardening  #podcast #gardentalk #vegetablegarden  #radio #influencer #gardentip #gardentalkradio #backyardgarden Email your questions to Gardentalkradio@gmail.com Or call 1-800-927-SHOW Segment 3: Dominique K of https://pharmunique.com/  Sponsors of the show for 2025 Phyllom BioProducts of http://www.phyllombioproducts.comPomona pectin of https://pomonapectin.com/Dripworks of https://www.dripworks.com/Walton's Inc of https://www.waltonsinc.com/  Us code grow50 and save 10% off your order of $50 or more Natural green products of https://www.natgreenproducts.com/ use promo code freeship4meany size No More Bugs!Rescue of https://rescue.com/Jung Seeds of https://www.jungseed.com/category/talk-gardening use code 15GT25 to save 15% off ordersWind River Chimes of https://windriverchimes.com/Wisconsin Greenhouse Company of https://wisconsingreenhousecompany.com/Mantis of https://mantis.com/Summit Chemical of https://summitchemical.com/Iv organics of https://ivorganics.com/  Use radio10 to save 10% off your orderSoilmoist.com of https://www.soilmoist.com/products/soil-moist.phpDavid J Frank of https://davidjfrank.com/ Timber Pro Coatings of https://timberprocoatingsusa.com/products/internal-wood-stabilizer/Totally tomatos of totallytomato.com/category/talk-gardening use code 15GT25 to save 15% off ordersr.h.shumway https://www.rhshumway.com/category/talk-gardening  use code 15GT25 to save 15% off ordersVermont Bean https://www.vermontbean.com/category/talk-gardening use code 15GT25 to save 15% off ordersEdmunds Roses use code https://www.edmundsroses.com/category/talk-gardening 15GT25 to save 15% off ordersRoot and Rhizomes https://www.rootsrhizomes.com/category/talk-gardeninguse code 15GT25 to save 15% off ordersKarrikaid https://karrikaid.com/ Use Code Radio10 at checkout and get 10% your order  Tarps https://tarps.com/Sunwarrior https://sunwarrior.com/ Use code JOEYHOLLY25” that will get you 25% off all productsat checkout Grow Smart https://www.grosmart.com/  use code “radio” at check out and save 10% on your order Lawn symergy https://lawnsynergy.com/Durable green bed https://durablegreenbed.com/Tree IV https://treeiv.com/Brome Bird Care https://bromebirdcare.com/en/Chip Drop https://getchipdrop.com/For Jars of https://forjars.co/  Use the code: forjars25 to get a 10% discount on your orderAzure https://www.azurestandard.com/ Use Promo Code: JOEYANDHOLLY15 applied at checkout to get 15% off for new customers who open an account for the first time and place a minimum order of $100 or more, shipped to a drop location of their choice.Corba head hand tools https://www.cobrahead.com/ use code soil for 10% your order at checkout valid once per customer Soil Savvy https://www.mysoilsavvy.com/Phyllom Bioproducts http://www.phyllombioproducts.com/home.htmlShore and Chore https://shoreandchore.com/Dig Defence of https://digdefence.com/Weed Wrench  https://www.weed-wrench.com/home us code weed at check out to save $10.00 on your order Milk weed balm of https://milkweedbalm.com/ Use code: gardening for 20% off your orderOne sweet earth of https://onesweetearth.com/Amazon #Influencer page with products we use and trust from gardening to camping, household goods and even cat stuff. Over 500 items list  https://www.amazon.com/shop/thewisconsinvegetablegardener?ref=ac_inf_hm_vp

Hypoglycemia can be subtle—or dangerously obvious—and knowing when and how to treat it is critical. In her first episode as our new Push Dose Pearls expert, Emergency Medicine Clinical Pharmacist, Haley Burhans, joins us to break it down. We discuss glucose thresholds by age, when to draw critical labs, and how to choose the right treatment—whether it's oral glucose, IV dextrose, or IM or intranasal glucagon. From neonates to older adults, Haley delivers practical, evidence-based pearls to help you manage low blood sugar safely and effectively in the ED. Was this episode helpful? What other medications would you like to learn more about? Hit us up on social media @empulsepodcast or at ucdavisem.com Hosts: Dr. Julia Magaña, Professor of Pediatric Emergency Medicine at UC Davis Dr. Sarah Medeiros, Professor of Emergency Medicine at UC Davis Guests: Haley Burhans, PharmD, Emergency Medicine Clinical Pharmacist at UC Davis Resources: Gandhi K. Approach to hypoglycemia in infants and children. Transl Pediatr. 2017 Oct;6(4):408-420. doi: 10.21037/tp.2017.10.05. PMID: 29184821; PMCID: PMC5682370. Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Haller MJ, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care. 2016 Feb;39(2):264-70. doi: 10.2337/dc15-1498. Epub 2015 Dec 17. PMID: 26681725; PMCID: PMC4722945.. MD Calc GIR (Glucose Infusion Rate) Calculator **** Thank you to the UC Davis Department of Emergency Medicine for supporting this podcast and to Orlando Magaña at OM Productions for audio production services.

Digging into ATP, Glutathione, and more:Scott Mulvaney and Dr. Nyan Patel discuss the benefits of glutathione, a powerful antioxidant crucial for detoxification and overall health. Dr. Patel, a pharmacist with 30 years of experience, explains the challenges of delivering glutathione orally and the success of his patented transdermal glutathione technology. He highlights the importance of maintaining high glutathione levels to combat oxidative stress and prevent diseases like Alzheimer's and Parkinson's. Dr. Patel shares his personal journey and success stories, including his father's significant health improvements after using his product. They emphasize the need for personal health accountability and the potential of glutathione to enhance brain function and athletic performance. Nayan Patel shared the story of his father, who at 84 underwent double knee replacements and quickly recovered, walking out of the hospital two days post-surgery. Despite being advised to rest, his father traveled extensively, including to India and Africa. Despite a fall resulting in a skull fracture and internal bleeding, his father remained positive and resilient. Nayan emphasized the importance of mindset and glutathione supplementation, which he believes played a crucial role in his father's recovery. He also discussed the broader impact of his work, aiming to help millions through his company, Auro Wellness, and his book, "The Glutathione Revolution."Quote: Fight Disease, Slow Aging, and Increase Energy with the Master Antioxidant! ~ Dr. Nayan Patel Your Co-Host Today:DR. NAYAN PATEL is a sought after pharmacist, wellness expert, and thought leader in his industry. He has been working with physicians since 1999 to custom develop medication for their clients and design a patient specific drug and nutrition regimen. He has been the pharmacist of choice to celebrities, CEOs and physicians themselves. He recently published his first comprehensive book, The Glutathione Revolution: Fight Disease, Slow Aging & Increase Energy. After 11 years of clinical research on the master antioxidant, glutathione, Dr. Patel and his team developed a patented technology to deliver Glutathione topically, changing the game on how best to absorb GSH systemically. From this technology he additionally developed The Auro GSH Antioxidant Delivery System to create a skincare line to deliver antioxidants more efficiently and effectively than ever before at potent concentrations. Today's Top 3 Takeaways:The topical delivery method of glutathione is far superior to oral, consumable, IV forms of delivery. Positive healthy impacts of glutathione use again oxidative stress, brain fog, neuroplasticity, cellular repair, and more. The benefits of serving yourself as an N-1 experiement, investing in functional medicine, regular blood work anlysis, and more. Today's Guest Co-Host Links:https://aurowellness.com/https://www.instagram.com/Aurowellness/https://www.facebook.com/aurowellnesshttps://www.tiktok.com/@auro.wellnesshttps://www.youtube.com/@aurowellness Watch us on YouTube:

A finales de la antigüedad irrumpió desde la estepa un pueblo que sembraría el terror y alteraría el curso de la historia del imperio romano: los hunos. Estos nómadas ecuestres, rápidos y muy diestros en el combate, iniciaron una migración hacia el oeste en el siglo IV que empujó a otros pueblos hacia el limes romano. Su llegada forzó a pueblos germánicos como los godos a buscar refugio dentro de las fronteras del imperio Romano, un movimiento que pondría en jaque a las dos porciones del imperio y terminaría provocando la desaparición de su parte occidental. Fue en el siglo V cuando la amenaza huna alcanzó su punto álgido bajo el mando de su figura más legendaria: Atila. Nacido en algún momento a principios del siglo V, Atila, junto con su hermano Bleda, heredó el control de una gran confederación de tribus. Tras el asesinato de Bleda en el 445 (un acto atribuido por las fuentes al propio Atila), Atila consolidó su poder sin oposición, construyendo un gran imperio que se extendía desde el Cáucaso hasta el Rin. Era un estratega brillante y un líder carismático, capaz de inspirar una lealtad férrea en sus seguidores y un pavor paralizante en sus enemigos. Se decía que donde pisaba su caballo, no volvía a crecer la hierba. Con Atila los hunos no solo exigían altos tributos a los imperios romano de Occidente y Oriente, sino que también lanzaban devastadoras campañas militares que dejaban a su paso ciudades en ruinas y poblaciones diezmadas. Su campaña más famosa comenzó en el año 451, cuando Atila dirigió a sus hordas hacia las Galias. Su objetivo era saquear sus ricas provincias, pero se encontró con una resistencia formidable. En los Campos Cataláunicos (cerca de la actual Châlons-en-Champagne), Atila se encontró frente a una improbable coalición formada por las legiones romanas del general Aecio y las fuerzas visigodas del rey Teodorico. Fue una de las batallas más grandes y recordadas de la antigüedad, un choque entre el poder nómada y la resistencia romano-germánica. Aunque la batalla terminó sin un vencedor claro, Atila sufrió grandes pérdidas y su avance fue frenado, lo que le obligó a retirarse de la Galia. Lejos de estar derrotado, al año siguiente, en el 452, dirigió su atención hacia Italia. Cruzó los Alpes y asoló ciudades como Aquileya, Mediolanum (Milán) y Pavía, dejando un rastro de destrucción. Cuando se acercaba a Roma, la capital del Imperio occidental parecía condenada. Pero, en un sorprendente giro de los acontecimientos, el Papa León I el Magno, acompañado por dos senadores de alto rango, salió al encuentro de Atila a las afueras de la ciudad. Lo que se dijo en esa reunión sigue siendo un misterio, pero el resultado fue que Atila decidió perdonar a Roma y retirarse de Italia, una decisión que algunos atribuyen a la persuasión papal y otros a factores logísticos como la escasez de provisiones y una epidemia en sus filas. La retirada de Italia marcó su último gran acto. En el año 453, en la misma noche de su boda con su última esposa, Ildico, Atila murió repentinamente en su lecho, quizá por envenenamiento. Su muerte fue tan rápida como su ascenso, y con ella, el imperio huno comenzó a desintegrarse a la misma velocidad a la que se había levantado. Sin el liderazgo unificador de Atila, las tribus que había sometido se rebelaron y el poder huno se disolvió en unos pocos años. Para hablar de este tema, que es una promesa que os hicimos Federico Romero y yo hace poco más de un mes, vuelve Federico a La ContraHistoria. Lo hace de la mano de Daniel Gómez Aragonés, que nos recibe en el museo de la España mágica de Toledo, un lugar de imprescindible visita en la ciudad imperial que hoy se ha transformado en un estudio de radio. Bibliografía: - "En defensa de Roma: Bárbaros al servicio del Imperio" de Federico Romero - https://amzn.to/4ls07S5 - Reinas godas" de Daniel Gómez Aragonés - https://amzn.to/4k97Sv9 - "Campos de gloria" de Pedro Santamaría - https://amzn.to/4l8BeuX - "El imperio huno de Atila" de José Antonio Molina - https://amzn.to/3T5UmgV · Canal de Telegram: https://t.me/lacontracronica · “Contra la Revolución Francesa”… https://amzn.to/4aF0LpZ · “Hispanos. Breve historia de los pueblos de habla hispana”… https://amzn.to/428js1G · “La ContraHistoria de España. Auge, caída y vuelta a empezar de un país en 28 episodios”… https://amzn.to/3kXcZ6i · “Lutero, Calvino y Trento, la Reforma que no fue”… https://amzn.to/3shKOlK · “La ContraHistoria del comunismo”… https://amzn.to/39QP2KE Apoya La Contra en: · Patreon... https://www.patreon.com/diazvillanueva · iVoox... https://www.ivoox.com/podcast-contracronica_sq_f1267769_1.html · Paypal... https://www.paypal.me/diazvillanueva Sígueme en: · Web... https://diazvillanueva.com · Twitter... https://twitter.com/diazvillanueva · Facebook... https://www.facebook.com/fernandodiazvillanueva1/ · Instagram... https://www.instagram.com/diazvillanueva · Linkedin… https://www.linkedin.com/in/fernando-d%C3%ADaz-villanueva-7303865/ · Flickr... https://www.flickr.com/photos/147276463@N05/?/ · Pinterest... https://www.pinterest.com/fernandodiazvillanueva Encuentra mis libros en: · Amazon... https://www.amazon.es/Fernando-Diaz-Villanueva/e/B00J2ASBXM #FernandoDiazVillanueva #atila #hunos Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

En este episodio de Hasta que se acabe el café, nos metemos en el mundo de las bodas EXCÉNTRICAS, esas ceremonias que parecen más conciertos, películas de ciencia ficción… o pura necesidad de likes

Ivák Bencét gyermekkorában egy tanára bántalmazta. Hamarosan videósorozatot indít Traumán Túl címmel, amelyben saját tapasztalatain keresztül mutatja be, hogyan lehet feldolgozni egy ilyen traumát. Bence emellett közösségi felületein is aktív, második éve vezeti a Gayciklopédia sorozatát.Elmondhatom Alapítvány: https://www.elmondhatomalapitvany.hu/A Partizán közössége bebizonyította azt, amiben sokan kételkedtek: a cselekvésnek van értelme, az összefogás meghozza az eredményét. A törvény elnapolásában elévülhetetlen érdemei vannak ennek a közösségnek.De ne feledd: bár ez egy fontos siker, egyelőre csak időt nyertünk!Folytatjuk közös történetünk!https://2026.partizan.huMaradjunk kapcsolatban!—A mögöttünk álló közösség biztosítja kérdéseink valódi erejét, fennmaradásunkat és függetlenségünket. Az alábbi módokon tudod támogatni munkánkat:Iratkozz fel!Értesülj elsőként eseményeinkről, akcióinkról, maradjunk kapcsolatban:https://csapat.partizanmedia.hu/forms/maradjunk-kapcsolatbanLegyél önkéntes!Csatlakozz a Partizán önkéntes csapatához:https://csapat.partizanmedia.hu/forms/csatlakozz-te-is-a-partizan-onkenteseihezTematikus hírleveleink—Szerdánként külpolitika: Heti Feledy hírlevélhttps://csapat.partizanmedia.hu/forms/partizan-heti-feledyPéntek Reggel, a Partizán hírháttér podcastjának levele: https://pentekreggel.huSzombaton Vétó hírlevél:https://csapat.partizanmedia.hu/forms/iratkozz-fel-a-veto-hirlevelereFacebook: https://facebook.com/partizanpolitika/ Facebook Társalgó csoport: https://www.facebook.com/groups/partizantarsalgo Instagram: https://www.instagram.com/partizanpolitika/TikTok: https://www.tiktok.com/@partizan_mediaPartizán RSS: https://rss.com/podcasts/partizan-podcast/Partizán saját gyártású podcastok: https://rss.com/podcasts/partizanpodcast/További támogatási lehetőségekről bővebben: https://www.partizanmedia.hu/tamogatas

On today's episode of The Pod At The Palace with Curtis Wilkerson: - It is NBA Draft day for Adou Thiero! Will he sneak into the first round? - What to make of Joe Lunardi's latest bracketology projections - Which Razorback is most likely to crack the rotation? SHOUTOUT TO OUR SPONSORS: BET SARACEN Arkansas' #1 Sports Betting App! Visit www.betsaracen.com to check out the latest spreads, lines, O/U, parlays, and more! BetSaracen has specials running every day that are unique to everyone here in the great, state of Arkansas! Download the BetSaracen app today on the Apple or Google Play store and get to winning big ONLY with BetSaracen…Arkansas' #1 Sports Betting App! https://apps.apple.com/us/app/saracen/id1612098207 FREEDOM BOAT CLUB Summer is finally here, and where is a better place to spend your summer than on the lake? Don't own a boat? Cool. You don't need to. Freedom Boat Club of Arkansas has you covered! Freedom Boat Club gives you access to boats—without the commitment. This is boating that fits your lifestyle—fun, flexible, and stress-free. They take care of the boat—so you can simply enjoy the moment. Whether you prefer Greers Ferry Lake, Lake Hamilton, or a day on the River in Little Rock, Freedom Boat Club of Arkansas will help make your summer in the Natural State the best one yet! Check out their Instagram page www.instagram.com/freedomboatclubarkansas today to learn more about the benefits of joining the club! BASIS HEALTH Basis Health is changing the way healthcare is delivered by providing mobile medical visits at the comfort of your home. A doctor will come to your home for urgent care, primary care, IV hydration and more! Basis Health… they are here for you when and where you need them most! Learn more at basishealth.org today! HICKEY & HULL LAW Divorce & custody cases are too important to try and face alone. Let Hickey & Hull Law provide you with persistent & diligent representation to help guide you through the entire process. They have handled THOUSANDS of family law cases & have experienced nearly every scenario that may come up. Hickey & Hull Law have offices across the state of Arkansas in Fayetteville, Fort Smith, Little Rock, & Mena. You can call them today at 479-434-2414 or you can check out their website! Visit www.hickeyandhull.com! It's Hickey & Hull Law…Things Are About To Get Better! HD ROOFING & CONSTRUCTION Storms can hit unexpectedly, so be sure to contact HD Roofing for your peace of mind with a free inspection. When you choose HD Roofing, you can rely on professionalism, top-quality materials and expert installation for all of your roofing needs! Learn more at HDArkansas.com! ALUMNI HALL 3417 N College Ave, Fayetteville, AR 72703 479-435-6352 www.insidearkansas.com/alumnihall The best and largest selection of Razorback gear Apparel for the family - mens, womens, kids, pets too Razorback apparel, accessories, hats, Yeti, gifts - Alumni Hall has it all Hall Pass Rewards - Earn points with your purchases and get rewarded! Once you've spent $150 (which is easy to do), you'll get $10 off your next purchase We know some athletes so for our friends that shop the big and tall Hogs gear - shop today at www.insidearkansas.com/alumnihall Alumni Hall - The ultimate Razorback shopping destination! LOOPER AUCTION & REALTY Why wait months—or even years—to sell your home the traditional way? At Looper Auction & Realty, we offer a faster, smarter option. Sell your home at auction. No repairs. No contingencies. No drawn-out negotiations. You set the terms, buyers compete, and you walk away with a firm closing date. Whether it's your home, an estate, or investment property, the auction method puts you in control—and gets it sold fast. Call Looper Auction & Realty at 479-996-4848 or visit LooperAuction.com. Looper Auction & Realty — Sold in 30, Closed in 30 Learn more about your ad choices. Visit megaphone.fm/adchoices

Sobre los detalles de la reformalización del ex alcalde Raul Torrealba, en el marco de la investigación de la Fiscalía por irregularidades en la municipio de Vitacura durante su administración y del libro realizado por el CEP, titulado “violencia en Chile, la fragilidad de orden social”, que estudia diversos aspecto de la violencia en Chile, Iván Valenzuela conversó con Andrea Vial y Angélica Bulnes, en una nueva edición de Rat Pack de Mesa Central.

En Columnistas de Mesa Central, Iván Valenzuela conversó con Constanza Schonhaut y Ximena Jara sobre las primarias oficialistas del domingo 29 de junio y los eventuales escenarios posteriores a la elección.

Andy and Nick are back with major announcements and unfiltered tour stories in this can't-miss episode! Here's what went down: Allie's having a baby! The guys celebrate band member Allie Kral's pregnancy with an emotional gender reveal (spoiler: it's a boy!) Nick's jam band video goes viral - Breaking down his controversial take that's got the whole scene talking Real talk about band finances - Andy gets brutally honest about spending on band dinners and tour expenses Health check with IV therapy - Why Andy's hooked up to IVs and what touring really does to your body Tour bus confessions - Uncensored stories about band dynamics, camaraderie, and life on the road Political hot takes - The guys dive into Middle East conflicts and current events (warning: opinions ahead!) Chaos phone calls - Multiple check-ins with band members lead to classic WSP moments Get ready for laughs, tears, and the brutal honesty you've come to expect from the World Saving Podcast. This one's for anyone who's ever wondered what really happens when the show ends and the tour bus rolls on. Watch this episode now on Volume.com & YouTube. We're psyched to partner up with Volume.com! Check out their roster of upcoming live events and on-demand shows to enrich that sweet life of yours. Call, leave a message: (720) 996-2403  Check out our new album Growing Pains on all platforms 5/23/25!! Follow us on Instagram @worldsavingpodcast For all things Frasco, go to: AndyFrasco.com Check out our sponsor, Gardenista: https://drinkgardenista.com/ Produced by Andy Frasco, Nick Gerlach, Joe Angelhow, & Chris Lorentz Audio mix by Chris Lorentz  

Welcome to New Money, Old Rules: The Gilded Age Podcast!  Join Caroline and Mike each week as they discuss HBO's period drama, The Gilded Age! Photograph by Karolina Wojtasik/HBO After just over 18months, The Gilded Age is BACK! And so is the New Money, Old Rules: The Gilded Age Podcast! This week, Caroline and Mike discuss The Gilded Age Season 3 Premiere, Episode 1, “Who Is In Charge Here?” Join in the conversation on Twitter at @podclubhouse and our Facebook Group, The Gilded Age Fan Group (HBO Series)! Listen, rate, review, and subscribe to New Money, Old Rules: The Gilded Age Podcast on Apple Podcasts, Spotify Podcasts, or wherever you listen! Please leave a 5-Star Rating! Also, write in and leave us comments on PodClubhouse.com, we'd love to hear from you! MORE IN THIS SERIES Season 1: Trailer | 1 | 2 | 3 | Kelli O'Hara Interview | 4 | 5 | 6 | 7 | 8 | Julian Fellowes and Sonja Warfield Interview | 9 | Harry and Rupert Gregson-Williams Interview Season 2: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 FOLLOW THE HOSTS ON X (F/K/A TWITTER) Caroline | Mike  ### Credits: Music: “String Quartet No. 12 in F Major, "American", Op. 96: IV" by Antonín Dvořák. New Money, Old Rules: The Gilded Age Podcast is a Pod Clubhouse original production, recorded and produced at Pod Clubhouse studios. This episode was edited by Caroline Daley and assembled by Michael Caputo.

THE LANCET 2003;362:772-776Background: Angiotensin converting enzyme inhibitors (ACEi) reduce mortality and morbidity in patients with systolic heart failure (see CONSENSUS and SOLVD trials). However, registry data showed that up to 20% of patients with systolic heart failure were not taking ACEi. One of the frequent causes for intolerance to ACEi is cough. Angiotensin converting enzyme inhibitors work by blocking the conversion of angiotensin I to angiotensin II, a key step in the renin–angiotensin–aldosterone system (RAAS). Angiotensin II receptor blockers were tolerated in patients with systolic heart failure who were intolerant to ACEi. However, data on long term effectives as an alternative to ACEi were lacking.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber.The Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Alternative trial sough to assess if the angiotensin-receptor blocker (ARB) candesartan, could improve outcomes in patients with systolic heart failure who are intolerant to ACEi.Patients: Eligible patients had left ventricular ejection fraction of 40% or less and NYHA class II, III or IV symptoms of at least 4 weeks duration. Patients had also to be intolerant to ACEi.Exclusion criteria were not provided in the main manuscript.Baseline characteristics: Patients were recruited from 618 centers in 26 countries. The trial randomized 2,028 patients – 1,013 randomized to receive candesartan and 1,015 to receive placebo.The average age of patients was 67 years and 68% were men. The average left ventricular ejection fraction was 30%. Cardiomyopathy was ischemic in 68% of the patients. The NYHA class was II in 48% of the patients, III in 49% and IV in 4%.Approximately 50% had hypertension, 27% had diabetes, 61% had prior myocardial infarction, 9% had stroke, 25% had atrial fibrillation and 14% were current smokers.At the time of enrollment, 85% were taking a diuretic, 46% were taking digoxin, 55% were taking beta-blockers and 24% were taking spironolactone.The most common reasons for ACEi intolerance were cough in 72% of the patients, hypotension in 13%, renal dysfunction in 12% and angioedema or anaphylaxis in 4%.Procedures: The trial was double-blinded. Patients were assigned in a 1:1 ratio to receive candesartan starting at 4 or 8mg once daily or placebo. The treatment was doubled every two weeks to a target dose of 32mg once daily.After randomization, follow up occurred at 2, 4, and 6 weeks, 6 months and every 4 months thereafter.Endpoints: The primary outcome was a composite of cardiovascular death or heart failure hospitalizations. All deaths were classified as cardiovascular unless there was a clear non-cardiac cause.Analysis was performed based on the intention-to-treat principle. The estimated sample size to have 80% power at 5% alpha was 2,000 patients. The sample size calculation assumed 18% relative risk reduction in the primary outcome with candesartan assuming a 15% annual event rate in the placebo arm.Results: The median follow up time was 34 months. The mean candesartan daily dose was 23mg at 6 months.Candesartan reduced the primary endpoint of cardiovascular death or heart failure hospitalizations (33.0% vs 40.0%, adjusted HR: 0.70, 95% CI: 0.60 – 0.81; p< 0.001). Candesartan reduced the individual components of the primary outcome - (21.6% vs 24.8%; p= 0.02) for cardiovascular death and (20.4% vs 28.2%; p< 0.001) for heart failure hospitalizations. All-cause death was also lower with candesartan (26.2% vs 29.2%, adjusted HR: 0.83, 95% CI: 0.70–0.99; p= 0.033). The number of patients who had any hospitalization as well as the total number of hospitalizations were numerically but not statistically significantly lower with candesartan (60.2% with candesartan vs 63.3%; p= 0.16) and (1,718 vs 1,835; p= 0.06).Candesartan was associated with more hypotension (3.7% vs 0.9%), more increase in creatinine (6.1% vs 2.7%) and more hyperkalemia (1.9% vs 0.3%). Angioedema occurred in three patients in the candesartan group and none in the placebo group. Cough occurred in two patients taking candesartan and four taking placebo.Authors reported no significant subgroup interactions, however, a corresponding graph was not provided.Conclusion: In patients with systolic heart failure who are intolerant to ACEi, candesartan reduced the primary composite outcome of cardiovascular death or heart failure hospitalizations with a number needed to treat of approximately of 14 patients over 34 months of follow up. Candesartan also reduced all-cause death with a number needed to treat of approximately 33 patients. Adverse events including hypotension, increase in creatinine and hyperkalemia were more common with candesartan.The reduction in the primary endpoint with candesartan was significant and offers an alternative for patients who are unable to tolerate ACEi. Of note, 72% of the patients enrolled in the trial were intolerant to ACEi due to cough. This trial did not include a head-to-head comparison between ARBs and ACEi, and therefore does not address which agent should be preferred as first-line therapy. Only 24% of participants were receiving spironolactone. The combination of ARBs with spironolactone, may increase the risk of adverse events, particularly hyperkalemia and kidney injury.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber. Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

The Arkansas Razorbacks have landed their first big domino in the transfer portal this afternoon in Ball State transfer Dylan Grego. Andrew Ellis breaks down the move and what it means for the roster on the latest edition of The Baumbastic Podcast! OFFICIAL MERCH: https://insidearkansas.myshopify.com/ #arkansas #razorbacks #football #basketball #baseball #sampittman #johncalipari SHOUTOUT TO OUR SPONSORS: BET SARACEN Arkansas' #1 Sports Betting App! Visit www.betsaracen.com to check out the latest spreads, lines, O/U, parlays, and more! BetSaracen has specials running every day that are unique to everyone here in the great, state of Arkansas! Download the BetSaracen app today on the Apple or Google Play store and get to winning big ONLY with BetSaracen…Arkansas' #1 Sports Betting App! https://apps.apple.com/us/app/saracen/id1612098207 ----------------------------------------------------------------------------- FREEDOM BOAT CLUB Summer is finally here, and where is a better place to spend your summer than on the lake? Don't own a boat? Cool. You don't need to. Freedom Boat Club of Arkansas has you covered! Freedom Boat Club gives you access to boats—without the commitment. This is boating that fits your lifestyle—fun, flexible, and stress-free. They take care of the boat—so you can simply enjoy the moment. Whether you prefer Greers Ferry Lake, Lake Hamilton, or a day on the River in Little Rock, Freedom Boat Club of Arkansas will help make your summer in the Natural State the best one yet! Check out their Instagram page www.instagram.com/freedomboatclubarkansas today to learn more about the benefits of joining the club! ----------------------------------------------------------------------------- BASIS HEALTH Basis Health is changing the way healthcare is delivered by providing mobile medical visits at the comfort of your home. A doctor will come to your home for urgent care, primary care, IV hydration and more! Basis Health… they are here for you when and where you need them most! Learn more at basishealth.org today! ----------------------------------------------------------------------------- HICKEY & HULL LAW Divorce & custody cases are too important to try and face alone. Let Hickey & Hull Law provide you with persistent & diligent representation to help guide you through the entire process. They have handled THOUSANDS of family law cases & have experienced nearly every scenario that may come up. Hickey & Hull Law have offices across the state of Arkansas in Fayetteville, Fort Smith, Little Rock, & Mena. You can call them today at 479-434-2414 or you can check out their website! Visit www.hickeyandhull.com! It's Hickey & Hull Law…Things Are About To Get Better! Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, we talk about: a permit test that was actually a test of bladder control, a teenage worker who was asked to come in and talk to the police, a girlfriend who is perceived as having an "attitude problem" by her boyfriend, a listener who had a TERRIBLE roommate, a wife bleeding out while waiting for her husband, and someone has a "come to Jesus" moment that leaves a relationship in shambles. ⁠⁠⁠⁠⁠⁠Judgies Merch is Available HERE!⁠⁠⁠⁠⁠⁠ Want fun, cool stickers and MORE? ⁠⁠⁠⁠⁠⁠www.aurorascreaturecorner.store⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠Palestine Children's Relief Fund⁠⁠⁠⁠⁠⁠ Donation Link Edited by: ⁠⁠⁠⁠⁠⁠https://www.youtube.com/@currentlyblinking⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠https://twitter.com/currentlyblink⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠https://tiktok.com/@currently.blinking⁠⁠⁠⁠⁠⁠ Our Patreon is officially open, if you want to see extra content go check it out!  ⁠⁠⁠⁠⁠⁠https://www.patreon.com/JudgiesPod ⁠⁠⁠⁠⁠⁠ Send us mail! (Addressed However You'd Like)  P.O. Box 58 Ottawa, IL 61350  Leave a Review!  ⁠⁠⁠⁠⁠⁠https://podcasts.apple.com/us/podcast/the-judgies/id1519741238⁠⁠⁠⁠⁠⁠  Follow us on Twitter: ⁠⁠⁠⁠⁠⁠https://twitter.com/judgiespod⁠⁠⁠⁠⁠⁠ Follow us on Instagram: ⁠⁠⁠⁠⁠⁠https://instagram.com/judgiespod⁠⁠⁠⁠⁠⁠  Intro Music by: Iván  ⁠⁠⁠⁠⁠⁠https://open.spotify.com/artist/5gB2VvyqfnOlNv37PHKRNJ?si=f6TIYrLITkG2NZXGLm_Y-Q&dl_branch=1⁠⁠⁠⁠⁠⁠  Time Stamps: 0:00 Intro 6:27 Wedding Date Changed 24:10 Left a Stain in a Bathing Suit 34:52 How To Salvage Relationship 41:10 Break 43:03 CJ: Music Video Comments 58:24 LS Sound 1:00:48 LS: Dad's iMessages 1:08:17 Pregnant GF Ruins Wedding 1:27:54 Pooping In Shower 1:32:38 Outro Story Links: Permit Test Work Incident Attitude Problem Bleeding Out "Jesus Moment" DELETED Learn more about your ad choices. Visit megaphone.fm/adchoices

  What if everything you learned about health and medical school is missing the real secrets to thriving, energetic living? In this premiere episode of the 2025 season of Health Hacks, Mark L. White pulls back the curtain on cutting-edge approaches that most doctors still aren't teaching—straight from one of Miami's leaders in regenerative and functional medicine, Dr. Kendrick Heywood. Episode Summary: Join host Mark L. White and guest Dr. Kendrick Heywood for a deep dive into the essential “five pillars” of health—covering everything from individualized nutrition, gene-driven exercise, optimal supplementation, hormone optimization, and breakthrough biohacks. Dr. Heywood reveals how he transitioned from traditional internal medicine to the forefront of anti-aging therapies, why most med schools still neglect these advancements, and how everyday patients (not just athletes!) can radically transform their health outcomes. Key Highlights: Myth-Busting Medicine: Discover why Dr. Heywood says 0% of what he uses today to optimize patient health was taught in med school. Personalized Diet & Exercise: Learn why the best approach for you isn't a fad diet—but a regimen designed for your unique genetic makeup. Hormone Optimization Demystified: Get the real story on hormone therapies, peptides, and why targeting the “top end” of health can change everything. Next-Level Biohacks: From red light therapy and hypberbaric chambers to exosomes and shockwave treatment—find out which futuristic tools Dr. Heywood recommends and why. Behind-the-Scenes Stories: Hear the incredible story of how Dr. Heywood saved NBA legend Dennis Rodman, and what it means to go above and beyond for patient care. Putting It Into Action—Listener Takeaways: Assess Your Pillars: Start by evaluating your own five pillars—are you optimizing each, or stuck in old routines? Get Personalized: Consider genetic testing to unlock your best diet and fitness plan, rather than chasing one-size-fits-all trends. Explore Biohacks Safely: Research and, if possible, consult with experts about the safest, most effective regenerative therapies (like red light therapy or IV vitamin drips). Ask About Hormones & Peptides: If you keep hitting fitness or wellness plateaus, consult a forward-thinking practitioner about hormone and peptide therapies tailored to your needs (not just based on “normal” ranges). Connect for Expert Guidance: Follow Dr. Heywood on Instagram (@drkenhaywood) for daily educational tips and updates on the latest in health optimization. Ready to take your health (and possibly your career) to the next level with strategies most doctors don't even know exist? Tune in—your path to a more thriving, energetic you starts here. Don't forget to subscribe to Health Hacks and visit omniwave.com for exclusive offers and more ways to take control of your health journey! Timestamped Overview 00:00 Anti-Aging Revolution in Miami 04:21 FDA Removes Testosterone Warning 08:53 Gene-Based Exercise Goals 12:24 Personalized Patient Care Evolution 15:27 Exploring Effective Biohacking Techniques 19:08 Becoming My Own Influencer 20:29 Hormones Aren't A Weight Loss Cure 24:22 Pioneers of Exosome Innovation 28:06 Elevating Influence and Global Outreach 29:49 "Health Hacks Podcast Promo"  

A la date du 18 mai 1945, on trouve dans les archives de la police du IVème arrondissement de Paris ce rapport : "Expulsion de M. Jean Marie, 33 rue des Francs Bourgeois, en vertu d'une décision de justice […] provoquant la réintégration à un M Rosenfeld, précédent locataire . Alors que l'opération était terminée, une centaine d'individus force le triple barrage établi et envahit l'immeuble. Les individus s'introduisent par la force dans le logement pendant que d'autres remontent pièces par pièces le mobilier. […] Ces individus déclarent qu'il est inadmissible de mettre des français à la porte pour réintégrer parfois des étrangers. Ils n'ont reçu aucune convocation et n'appartiennent à aucune organisation." Ce jour-là on assiste donc à une manifestation contre la restitution d'un appartement à son ancien locataire. Sarah Gensburger, sociologue au CNRS/Sciences Po Paris, Isabelle Backouche, historienne à l'EHESS et Eric Le Bourhis, historien à l'Inalco, ont mené une grande enquête pour comprendre comment les rescapés de la Shoah ont subi la nouvelle épreuve de retrouver leur appartement, à leur retour à Paris. Dans leur livre Appartements témoins, la spoliation des locataires juifs à Paris, 1940-1946, (Editions La Découverte, 2025) il et elles nous racontent une autre histoire de l'Occupation et surtout de la Libération. Photo : Rue des Francs-Bourgeois, Paris IIIème, 1945, théâtre d'une manifestation antisémite le 18 mai 1945 (Copyright : Toulouse / Direction de l'Urbanisme / Ville de Paris / Archives de Paris).

En Ivoox puedes encontrar sólo algunos de los audios de Mindalia. Para escuchar las 4 grabaciones diarias que publicamos entra en https://www.mindaliatelevision.com. Si deseas ver el vídeo perteneciente a este audio, pincha aquí: https://www.youtube.com/watch?v=sruAn2dW-X8 La inocencia es un reconocimiento de la naturaleza inmaculada que nunca ha entrado en contacto con la vergüenza, la culpa, la apatía, el miedo o la ira. Es ese niño interior que conoce la Fuente de la Creación y vive con total confianza. ¡Ríndete a la Inteligencia de la Vida y permítete ser un NIÑO DIVINO! Iván Bava Maestro espiritual croata que ha establecido sus escuelas de Conciencia y Maestría Espiritual en España, India, Eslovenia y Croacia, con sus centros de retiros en India y Croacia. https://ivanbava.mailerpage.io/ / ivan_bava / @escuela.conciencia http://www.x.com/@bavcevic Más información en: https://www.mindalia.com/television/ PARTICIPA CON TUS COMENTARIOS EN ESTE VÍDEO. ------------INFORMACIÓN SOBRE MINDALIA----------DPM Mindalia.com es una ONG internacional, sin ánimo de lucro, que difunde universalmente contenidos sobre espiritualidad y bienestar para la mejora de la consciencia del mundo. Apóyanos con tu donación en: https://www.mindalia.com/donar/ Suscríbete, comenta positivamente y comparte nuestros vídeos para difundir este conocimiento a miles de personas. Nuestro sitio web: https://www.mindalia.com SÍGUENOS TAMBIÉN EN NUESTRAS PLATAFORMAS Facebook: / mindalia.ayuda Instagram: / mindalia_com Twitch: / mindaliacom Odysee: https://odysee.com/@Mindalia.com *Mindalia.com no se hace responsable de las opiniones vertidas en este vídeo, ni necesariamente participa de ellas.

Welcome to our new show where we give legally not advice to our listeners! Call (850)JUDGIES to leave us a voicemail asking for some of our (again, not legally) advice! In this episode, we talk about: a caller whose had a couple of smokes and a couple of drinks, a caller that wants to be more petty with their SIL at an upcoming wedding, and we go over the Rod Blagojevich Saga one caller had experienced. ⁠⁠⁠⁠⁠⁠⁠Judgies Merch is Available HERE!⁠⁠⁠⁠⁠⁠⁠ Want fun, cool stickers and MORE? ⁠⁠⁠⁠⁠⁠⁠www.aurorascreaturecorner.store⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠Palestine Children's Relief Fund⁠⁠⁠⁠⁠⁠⁠ Donation Link Edited by: ⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@currentlyblinking⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠https://twitter.com/currentlyblink⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠https://tiktok.com/@currently.blinking⁠⁠⁠⁠⁠⁠⁠ Our Patreon is officially open, if you want to see extra content go check it out!  ⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/JudgiesPod ⁠⁠⁠⁠⁠⁠⁠ Send us mail! (Addressed However You'd Like)  P.O. Box 58 Ottawa, IL 61350  Leave a Review!  ⁠⁠⁠⁠⁠⁠⁠https://podcasts.apple.com/us/podcast/the-judgies/id1519741238⁠⁠⁠⁠⁠⁠⁠  Follow us on Twitter: ⁠⁠⁠⁠⁠⁠⁠https://twitter.com/judgiespod⁠⁠⁠⁠⁠⁠⁠ Follow us on Instagram: ⁠⁠⁠⁠⁠⁠⁠https://instagram.com/judgiespod⁠⁠⁠⁠⁠⁠⁠  Intro Music by: Iván  ⁠⁠⁠⁠⁠⁠⁠https://open.spotify.com/artist/5gB2VvyqfnOlNv37PHKRNJ?si=f6TIYrLITkG2NZXGLm_Y-Q&dl_branch=1⁠⁠⁠⁠⁠⁠⁠  Time Stamps: 0:00 Intro 1:52 Smoking and Drinking 9:00 How to Be Petty with SIL 17:29 3 Wines and a Smice 21:21 Rod Blagojevich Saga 37:40 Catching Sand Fleas Learn more about your ad choices. Visit megaphone.fm/adchoices